Education
About Us
Working with TipRanks
Follow Us
Aspen Pharmacare (APNHY)
OTHER OTC:APNHY
APNHY Stock Chart & Stats
$6.80
$0.00(0.00%)
At close: 4:00 PM EST
$6.80
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$5.24 - $9.98
Previous CloseN/A
Volume14.00
Average Volume (3M)710.00
Market Cap
$3.49B
Enterprise Value$86.16B
Total Cash (Recent Filing)$5.61B
Total Debt (Recent Filing)$32.91B
Price to Earnings (P/E)8.6
Beta0.27
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.15%
Share Statistics
EPS (TTM)0.19
Shares Outstanding446,252,320
10 Day Avg. Volume0
30 Day Avg. Volume710
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.63
Price to Sales (P/S)1.23
P/FCF Ratio512.59
Enterprise Value/Market Cap24.71
Enterprise Value/Revenue2.29
Enterprise Value/Gross Profit5.46
Enterprise Value/Ebitda53.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.79
Revenue Forecast (FY)$2.49B
Bulls Say, Bears Say
Bulls Say
Commercial Pharma MarginsA high‑margin Commercial Pharma division showing mid‑single digit revenue growth and double‑digit EBITDA expansion provides durable earnings resilience. Stable ~29% EBITDA margins concentrate profit generation in a less cyclical, branded/retail channel, supporting cash flow and reinvestment over the medium term.
Improving Cash & APAC DivestmentSubstantial operating cash generation plus a planned APAC disposal that could eliminate most net debt materially strengthens liquidity and deleverages the balance sheet. This structural improvement increases financial flexibility for capex, restructuring, and reduces interest burden over multiple quarters.
Product Momentum & Recovery PipelineGrowing GLP‑1 franchise and planned generic launches create sustainable commercial tailwinds. Combined with insulin ramp, RFQs in France and targeted sterile recovery actions, these durable product and contract wins can rebuild higher‑margin volumes and restore manufacturing returns over 2–3 years.
Bears Say
Manufacturing & Sterile CollapseThe loss of a major mRNA contract and resulting ~85% EBITDA drop in Manufacturing is structural, revealing contract concentration and operational risk. Persistent underutilization and restructuring needs can depress margins and ROIC for multiple reporting periods until new contracts and sterile profitability are secured.
Weak Cash ConversionSeverely weakened free cash flow conversion signals impaired cash generation quality; an OCF/NI ratio of 0.29 and near‑zero FCF/NI leave little buffer for investment or debt paydown. Sustained weak cash conversion constrains strategic flexibility and elevates refinancing and execution risk over the medium term.
Elevated Leverage & ROIC WeaknessHigh net debt and acknowledged ROIC deterioration indicate capital is not generating expected returns. Until divestment proceeds are realized and ROIC trends reverse, elevated leverage plus legacy underperformance increases vulnerability to currency, regulatory and funding shocks and limits long‑term value creation.
Aspen Pharmacare News
APNHY FAQ
What was Aspen Pharmacare’s price range in the past 12 months?
Aspen Pharmacare lowest stock price was $5.24 and its highest was $9.98 in the past 12 months.
What is Aspen Pharmacare’s market cap?
Aspen Pharmacare’s market cap is $3.49B.
When is Aspen Pharmacare’s upcoming earnings report date?
Aspen Pharmacare’s upcoming earnings report date is Sep 02, 2026 which is in 172 days.
How were Aspen Pharmacare’s earnings last quarter?
Aspen Pharmacare released its earnings results on Mar 03, 2026. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of N/A by $0.19.
Is Aspen Pharmacare overvalued?
According to Wall Street analysts Aspen Pharmacare’s price is currently Overvalued.
Does Aspen Pharmacare pay dividends?
Aspen Pharmacare pays a Annually dividend of $0.122 which represents an annual dividend yield of 2.15%. See more information on Aspen Pharmacare dividends here
What is Aspen Pharmacare’s EPS estimate?
Aspen Pharmacare’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aspen Pharmacare have?
Aspen Pharmacare has 446,252,320 shares outstanding.
What happened to Aspen Pharmacare’s price movement after its last earnings report?
Aspen Pharmacare reported an EPS of $0.19 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.191%.
Which hedge fund is a major shareholder of Aspen Pharmacare?
Currently, no hedge funds are holding shares in APNHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aspen Pharmacare Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.29%
12-Months-Change
Fundamentals
Return on Equity
-1.18%
Trailing 12-Months
Asset Growth
0.34%
Trailing 12-Months
Company Description
Aspen Pharmacare
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. The company was founded in 1850 and is headquartered in Durban, South Africa.
APNHY Company Deck
APNHY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveys a balanced picture: strong operational cash generation, clear commercial pharma momentum (notably GLP‑1 traction), and a material APAC divestment that should materially strengthen the balance sheet and unlock shareholder value. Offsetting these positives are significant near‑term manufacturing and sterile segment setbacks (large EBITDA and revenue hits from lost contracts), a meaningful short‑term decline in group earnings, and ongoing macro/regulatory and currency risk. Management presented a defined recovery plan (cost reshaping, contract commercialization, insulin ramp, French site wins and sterile restructuring) and targets FY27 restoration of prior EBITDA levels, but execution is required to convert the improvements signaled into sustainable results.View all APNHY earnings summariesTechnical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Alvotech
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---